Scholars@Duke publication: Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials

Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials

Publication , Conference

Pope, J; van der Heijde, D; Weinblatt, M; Landewe, RB; Goel, N; Wells, AF; Fleischmann, R

Published in: JOURNAL OF RHEUMATOLOGY

2009

JOURNAL OF RHEUMATOLOGY

0315-162X

2009

2603 / 2603

APA

Chicago

ICMJE

MLA

NLM

Pope, J., van der Heijde, D., Weinblatt, M., Landewe, R. B., Goel, N., Wells, A. F., & Fleischmann, R. (2009). Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials. In JOURNAL OF RHEUMATOLOGY (Vol. 36, pp. 2603–2603).

Pope, Janet, Desiree van der Heijde, Michael Weinblatt, Robert B. Landewe, Niti Goel, A. F. Wells, and Roy Fleischmann. “Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials.” In JOURNAL OF RHEUMATOLOGY, 36:2603–2603, 2009.

Pope J, van der Heijde D, Weinblatt M, Landewe RB, Goel N, Wells AF, et al. Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials. In: JOURNAL OF RHEUMATOLOGY. 2009. p. 2603–2603.

Pope J, van der Heijde D, Weinblatt M, Landewe RB, Goel N, Wells AF, Fleischmann R. Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials. JOURNAL OF RHEUMATOLOGY. 2009. p. 2603–2603.

JOURNAL OF RHEUMATOLOGY

0315-162X

2009

2603 / 2603